
Cell/Gene/RNA engineering to cure cancer @DanaFarber, @harvardmed, @broadinstitute, formerly @sloan_kettering, #CART
Boston, MA
Joined November 2014
- Tweets284
- Following920
- Followers1.5K
- Likes584
Pinned Tweet
Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and could not be done without the amazing clinical, correlative science, stats, & cell manufacturing teams.
Happy to share our bench>bedside journey
1/10
So exciting to see the first clinical data of the dual- BCMA/GPRC5D CAR! Congrats D Hansen @MoffittNews, C Mo @DanaFarberNews, S Mailankody @MSKCancerCenter and all the clinical teams leading this study + K Harrington and @bmsnews cell tx teams. #ims26 #mmsm @fdezdelarrea
CONGRESS | #IMS26 | PRESENTATION
Doris Hansen, Moffitt Cancer Center, presents initial findings from a phase I trial investigating BMS-986453 in patients with RRMM (N = 58).
Patients were administered 25, 75, 150 or 300 million (M) CAR T-cells. At median FU of 12 months, ORR was 83% for all doses. In patients who were BCMA/GPRC5D-naïve and treated with 75 or 15 million CAR T cells (n=16), ORR was 83%, and 100% achieved ≥VGPR and were MRD(−) at 10⁻⁵ threshold. Dose-limiting toxicities occurred in 19% of patients. Grade 3/4 TEAEs were reported in 98% of patients; neutropenia (88%) and thrombocytopenia (48%) were the most common.
Follow our live feed for more updates: bit.ly/4cWKNew
Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.
#MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @MoffittNews
Eric Smith retweeted
Excited to present preclinical data on #VV169 #InVivoCART Abstract Session 14 #IMS26. First-in-human trial is now open @MayoCancerCare true academic & pharma collab that will enable us to examine the mechanism of action in depth on trial @VyriadMN @JoselleCookMD @ESmithMDPhD
Abstract Sessions begin at 1:00 PM. Join us in Hall 5 for Abstract Session 13 or Lomond Auditorium for Abstract Session 14. #IMS26
Eric Smith retweeted
Look forward to presenting our research on the epigenetic effects of high blood sugars on CAR T outcomes as well as mechanisms to reverse this on behalf of our team - @Yael_David__ @ESmithMDPhD This collaborative project includes in vitro, in vivo & clinical data. #IMS26 #mmsm
Tomorrow at #IMS26: MSK myeloma specialist @UrviShahMD will present research on targeting a metabolic-epigenetic axis to improve CAR T therapy in multiple myeloma. @Myeloma_Society
🗓️ Saturday, September 26 | 11 a.m. BT / 6 a.m. ET
Eric Smith retweeted
Inspired by Gibson cloning, we describe prime assembly, now published, for in cellulo targeted integration of gene-sized DNA fragments using prime editing. nature.com/articles/s41586-0…
Seeing a CAR we engineered cross the threshold into patient care is the most meaningful milestone.
lnkd.in/p/d2_FkVwF
Eric Smith retweeted
As a 10-year Hodgkin lymphoma survivor, I’ve personally benefitted from research progress. I will join over 20 woMMen physicians on a hike in the Scottish highlands to support @HealthTree & a scholarship! Please consider supporting & sharing #mmsm
give.healthtree.org/urvishah
A meaningful milestone for Arlo-cel (GPRC5D CAR for myeloma): Registration phase II top line results reported. One step closer toward potential approval and bringing a new treatment option for patients. news.bms.com/news/details/20… #MMsm
Eric Smith retweeted
Every so often, a major event happens in your life to validate years of work. SRRK’s ISEMBYLD was FDA approved. Having participated in its development from basic science to approval, as a physician-scientist, this is one of my best days. Happy for ISEMBYLD to help SMA patients.
Eric Smith retweeted
🚨Today in @Cancer_Cell: 50,000 tumor genomes via MSK-IMPACT. We map which HLA alleles are highest yield for antigen discovery—and define when HLA LOH constrains targetability.
A framework for scaling TCR therapies.
@MSKCancerCenter @parkerici authors.elsevier.com/sd/arti…
Honored to be recognized w/ past + current Investigators @AhrensNicklas @AnguelaXavier & @DevermanLab. Award is to our entire @DanaFarber gene and cell therapy team & the huge teams of colleagues past/present who work to bring these therapies from ideas in the lab to patients.
Congratulations to Eric Smith, MD, PhD, @DanaFarber on receiving the Outstanding New Investigator Award from @ASGCTherapy. Smith will present on advancing CAR T cell therapy for cancer immunotherapy. #ASGCT2025
Eric Smith retweeted
Congratulations to Eric Smith, MD, PhD, @DanaFarber on receiving the Outstanding New Investigator Award from @ASGCTherapy. Smith will present on advancing CAR T cell therapy for cancer immunotherapy. #ASGCT2025
Amazing work Ko-Wei Liu and the collaborative team to engineer CAR T cells where persistence is controlled by leveraging @CueBiopharma recombinant ImmunoSTATs to specifically deliver TCR+cytokine signals to our engineered cells. #asgct25 #asgct2025 @DanaFarberNews
2
4
535
Congrats @EJBrea on awesome work and an awesome presentation showing how CAR T cell therapy can overcome ADC resistance in solid tumors and engineering rational biparatopic CARs. #asgct2025 #asgct25 @DanaFarberNews
1
5
435
Congrats @LizCarstensMD on your outstanding presentation on engineering novel CARs to enhance the therapeutic window of CAR T cells for GI malignancies. #asgct2025 #asgct25 @DanaFarberNews
8
599
Participated recently in the @WhiteHouse Cell & Gene Therapy Forum. Patient advocates, rare disease families were inspiring. Massive science advances (CAR T, sickle cell GT). Need to ensure ACCESS. Scientific AND policy solutions must be prioritized. #WhiteHouseCGT h/t @KamalMe.
Congrats to CAR T pioneers for work done @MSKCancerCenter (where I was lucky enough to get my start): @BrentjensRenier, Michel Sadelain, as well as @carlhjune (@pennmed) and Zelig Eshhar (@WeizmannScience) on winning the 2024 Warren Alpert Prize for CAR T cell tx! Well deserved!
The 2024 Warren Alpert Prize honors four pioneers in CAR T-cell therapy bit.ly/3KCiSlw
22
1,013
Thanks @robin_shattock for bringing this to our attention. There is no evidence that mRNA vaccines cause cancer and these claims should not be a hurdle to progress with RNA technology being developed to benefit our patients.
This Post is from an account that no longer exists. Learn more
6
1,016
Amazing being part of @IOTNmoonshot thank you to all who made this incredible network possible.
Replying to @NCI_CIPNet
Co-Chairs Drs. Catherine Bollard and Eric Smith @ESmithMDPhD expressed heartfelt gratitude to all members for their enthusiasm and contributions. Thank you all for your support, and we eagerly anticipate seeing you at the capstone meeting in May!
7
813




























